Biocon Corporate Presentation

Research Services: Q1 FY22 KEY HIGHLIGHTS Growth across all divisions - Discovery, Development and Manufacturing services Significant contribution of Remdesivir in topline growth Syngene Q1 FY22 Q 1 F Y 21 Revenue *595Cr *422Cr 41% YoY increase Mangalore API facility successfully completed ISO 9001:2015 certification audit Profit Before Tax *95Cr *66Cr 16% of revenue Signed a five-year agreement with IAVI for manufacturing three anti-HIV mAbs for use in Phase 1 and 2 clinical trials 17

View entire presentation